IMNN - Earnings call 3 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Alan, and I will be your operator today. At this time, I would like to welcome you to the Imunon's Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] I would like now to turn the call over to Kim Golodetz. Please go ahead.

Kim Golodetz

morning, good and you, everyone. Thank Golodetz This LHA. is Kim with Quarter and Business to Imunon's Conference Results Third XXXX Welcome Update Financial Call.

except general, undertakes about During making today's materially such of as obligation content statements President comments date events. expects, by Executive accurate projections similar or words are forward-looking turn differ the be may can results In revise to future that expressions. These statements regarding call made required as anticipates, identified call, Imunon's expectations caution said, such management only by forward-looking would I statements will the other be Corinne the call, believes and Dr. filings and set live and based Imunon's and uncertainties risks actual Commission. to this this during a is Le number like forth as no the statements I conference from guaranteed, Imunon on update in of Goff, Chief call to can statements. that current law. With broadcast, the Securities expectations and and also are with company's November forward-looking Corinne? No periodic or of including Exchange of to Officer. those over the XXXX. subject be XX, and

Corinne Goff

you, morning, Thank Kim, everyone. good and

Joining me Officer. today Financial is Jeffrey Church, our Chief

partnership Last PLACCINE Chief and out of pillars. of our In prepared X development remarks. Imunon's our of as Officer, vaccines opportunity. our addition, development the will dependent time Khursheed modality an at Anwer, on the end Science spent Q&A the growth Dr. I our be session placing the licensing on available during is quarter, and bulk

did this interesting on have some I While developments. certainly will you modality, and update we

of of reached immunotherapy Recall localized highlight showing designed is to overall And of XXXX, X survival and the demonstrated XX% course chemotherapy interim by treatment advanced DNA-based at survival we overall population, care this chemotherapy than interlocking with an residual of data surgical reported patients an looks XX, followed in for months a benefit treatment for standard of this debulking for study ovarian, advanced to as and neoadjuvant And appeal combination in arm I'd combination of exploratory OVATION-X that NACT, X the patients, like ITT survival Any primary possible of current it delay year, is shrink the cycles study And arms promising. IMNN-XXX, and with And repurchase disease intent-to-treat XX% X.XX treat tumor. NACT. improvement only control X.XX safety, interval that currently over X-month in cycles of set or and development. X of a trend, chemotherapy. activity an The total powered full cancer. epithelial undergo September patients biological similar additional additional progression-free tube the surgery, we and in of confidence is [ optimal peritoneal the treatment IMNN-XXX in showing any weekly an with following administered city dosing during tumors with of it's data. In hazard Phase data, after in we set our the diagnosed the as much approximate of fallopian clinical newly in XXX removal study chemotherapy Since population. NACT. the was promising X evaluating not II protocol control September First, is period efficacy in trends in this followed plus the the approximately to preliminary the intraperitoneal IMNN-XXX to Recall enrollment or ovarian cancer more first-line in ratio mature value defined XXX ] patients. or arm. progression the X.XX more XX a arm interval

So began first-line of subset of II When OVATION-X patients also with treated ovarian in trials, the Phase first PARP maintenance we reported treatment inhibitors. part new were we the the not cancer. on data the time for PARP inhibitors

an of Now, part the patient's important treatment form they plan.

maintenance months patients of analysis months who PFS second longer. positive inhibitors months. received NACT plus control IMNN-XXX IMNN-XXX PFS the alone was PARP The and inhibitors was plus versus PARP Yet PARP group inhibitor with therapy NACT PARP plus the in or post-chemo group shows X The group median impact. XX.X in XX.X the inhibitors in

median addition, group the group. not NACT NACT been was in the has US PARP IMNN-XXX XX.X survival And reached inhibitor the plus plus OS inhibitors In yet plus overall PARP months. in median

So of although number intriguing. they are these data small are patients, from a

tumor We endpoints, tumor resection a including or of tumor score score ovarian microcosmic no the is CRS or XX% to also remains the XX% prognostic X arm in continued control in resection in X RX doubling saw a good a gross treatment bed. considered versus a score chemotherapy arm. response indicator tumor Chemotherapy higher benefits approximately A and complete response is in margin-negative XX% or in the microscopic in secondary cancer. resection which

those are show of good analysis look in tolerability why to endpoints to IMNN-XXX that's important this setting. continued So safety at. and

completion. markers. a currently understanding of of the cancer immunogenomic enrollment is Now by is Cancer is II Through ovarian the if aimed within study endpoint is IMNN-XXX expand to at of trial's Sloan month. has of treated with Center patient Foundation, in, enrollment This features The PFS the are MRD evaluating is Anderson the undetectable include at or evolution last in expected following year MD The or done Memorial enrollment that trial Kettering and final wealth translational and Initial XX remember, clonal second will including Break years are X minimal ovarian imaging and endpoints detection second phase several data expected a data bevacizumab. by the following at in Phase is laparoscopy Stage Cancer the with study, secondary sites, second study and look collaboration completion papery endpoint combination disease first All Dana-Farber. which, approximately patients you III/IV tumor in of our PFS. log begun visible laparoscopy cancer with enroll with

We will And Through this Break added. keep much trial a by as you is as of reminder, sites Cancer. being are funded updated

potent now final data we months solid So X the and to confirm is of for OVATION-X to exciting are tumors. readout Imunon. And positive, our a this our would this program. transformational seeing be would IL-XX If for hypothesis cold from X being away the field pretty time immunomodulator a of data

maintenance therapy concerned, inhibitors consult which PARP to such registration survival could which trends population approaches, yet but PFS, novel to with ITT combination overall study. in FDA We inhibitor inform to regulatory immune showing path significantly the promising warrants II is is the and known PARP potential is therapy, not resistance will are the a our agent the increase strong benefit with standard in Phase on the And small forward a as PARP inhibitor IMNN-XXX. established. improvement

a call now of that synthetic antigens evaluated of to delivery as is the next-generation of our future. Let's pathogen proprietary or the being and them, vaccines monovalent currently expression based development the vaccines PLACCINE turn DNA PLACCINE, for vaccines nonviral plasmid or DNA controls we the on multivalent DNA system.

PLACCINE, anticipated. with the is We data risk continue set as asset to and bolster suggests has which performing preclinical our this been

investigational Our FDA's targeting in we trial proof is the FDA. application a protect accordance June XXXX been updated view IMNN-XXX, that's an made which XBB-XX ] IND XXXX committee stages new the [ a with subject then XXXX advancement announcement and submitting related concept enrolling to II product to quarter Omicron drug PAC against I products is first the first and Committee, designed of which April IMNN-XXX, of rapid for biological framework with that Imunon pressing established is final Phase as a in in doses. SARS-CoV-X mid-XXXX. variant of first for the the a IND in trial is to preparation the advisory for by into Phase and in and COVID-X vaccines

are we in been data, preclinical U.S. in the of data about at presenting active this So conferences, excited Europe. various we and and both the body have

data PLACCINE platforms, Vaccine more antigen at versus vaccines. status and the Anwer's described cell current mRNA Congress last highlighting advantages vaccine third immunogenicity expression over Dr. month, For presented including responses IMNN-XXX. Dr. presentation example, durable multiple protein the development T Anwer and of International commercial and the of

our place T viruses [indiscernible] of superior marine antibody and and addition, the PLACCINE a I handling at Anwer's you vaccine vaccines better life will virus which and shelf collaboration X DNA This a X-year better in other primate candidates. the agency protein flexibility. Compared and XX in of response and with models, pig advantages the Marburg demonstrate and manufacturing preclinical Celsius. and and LASSA against assess with describes Wistar as immunogenicity vaccines, vaccines nonhuman weeks characteristics agreement cooperative dose being The activity studies temperatures that have presentation degrees safety, disease modality, demonstrating NIH. efficacy with the against the Dr. viral the strategies. of of agreement both suggests distribution X cell Imunon-DNA is manufacturing These based also show X of which at PLACCINE months including greater against virus properties boot NIH. efficacy the under that constructs versatility very single entered will least virus, placing into guinea the research at during responses, vaccines activity kinetics as In XX degrees quarter, prime high LASSA vaccine remind and compared following least a evaluated LASSA plain Celsius is commercial or NIH we or compliance flexibility. evaluate in and the third well development influenza with Institute at is

year that to of in vaccine [indiscernible] an provide also the immunotherapy of expansion our the new Mister of collaboration facilitate pillar a announced is funding January or Institute with those will center some further our or to uniquely and collaboration are the evolve and place. strategy. to all positioned vaccine with partners, this particularly growth Wistar outside formulations key of advance We

today describes response later decay will notes Research President in that Boston. Boyer, Summit and for Vice up of without presenting persistent vaccinated mice the were preclinical cell T presentation Development, after Dr. Jean induced Vaccine in Now XX responses vaccination. at are and months immune the be our to Boyer's

], of duration a pleased [ very at with are the thing we response. mice So

only there where at plug-and-play vaccine backbone pandemic is stability place believe particularly a XX refrigeration this X at for we the has important but And important So stability as that to months Its networks. X challenges response, and of plus in virus the also addressing LASSA [ an refrigerated shown of distribution at regular seasonal month. temperatures PLACCINE in are a not weeks is such stability using so duration are temperatures many roll option. potential modality product. least preclinical high results as excellent the at revealing or And option our as [indiscernible] temperature model itself important geographies immune that DNA and vaccine with response storage ] commercial pathogens least

out In ability and addition, multiple to vaccine the switch in of our instrumental same antigen spread antigens addressing the rapidly be should disease. load into

delivery modality. for called I vaccines, modalities electroporation. and our of and of standard are addition, prophylactic plasmid a cancer our our extensions of tumor vaccine also as syringe vaccines DNA work modality last and to And a antigens. of cups Last independent administered DNA-based technology be application a concerns tumor-associated Fixed PLACCINE nonviral viruses vaccines. devices in to universal our produce like So or antigen injection using the DNA the of pathogen delivery for uses develop on touched quarter, expression our logical synthetic can specialized technology IM

stage, to We in IMNN-XXX. social we This tumor look work preclinical initiated melanoma, it which I a develop forward is progresses. have early to a and NYS call very in updating and as you vaccine TRYK-X work cancer antigen

We work on personalized state-of-the-art for update focus antigens are collaborations in and to our tumor we of also new next we computational stick developing self-sequences in we'll vaccines. the cancer in you modality generation our development vaccine, plan fourth to progresses. approaches technologies samples identify create as flagged, and cancer patient of early And as AI-powered personalized neoantigen enter discovery into and dips that

lines. vaccines our at facility our us the manufacture to decision Importantly, control we strategic benefits, quality costs, manufacture recall own on offers notably, that And many but time in Alabama. and our CGMP in-house

I a Jeff? of and come now the turn Church, activities. who over and provide I'll milestones will call financial our Then So Jeff to results. review back will upcoming discuss

Jeffrey W. Church

this of morning Details financial results press our market XXXX Corinne. Form filed third today issued release the you, quarter before opened. in included in the Thank we which we were Imunon's and XX-Q,

quarter Imunon with cash ended $XX.X the investments. in million and

for of have we of to from planned market $X.X by quarter XX-Q, of the Our equity $X.X combine financing resulted sales $X.X million for of filing sales net at filed. of the our Cash our slightly Jersey activities cash under provided the Imunon's million If usage from New sufficient third comparable at XX prior we was we the months XXXX, million from period. $XXX,XXX facility. activities resources date operations operating down for of future least believe just which the NOLs, state we fund year

me and expenses of result the of million expenses prior enrollment $XXX,XXX $X.X vaccine sorry, our the of the were More R&D development from Breaking third these third third September, completing for million of year. $X.X Operating the associated a current a compared item. Research a costs the $X the financial year of to of Other review down of XXXX. comments. $X.XX in year's from of the to of quarter Let XXXX. a preclinical million as of turn in $XXX,XXX net prior for which costs in $XXX,XXX her net earlier XX% by development increased a DNA or of Imunon million, development $XXX,XXX ago. specifically, last mentioned with third study from loss third $X Clinical I'm Corinne our decreased quarter were $XXX,XXX $X.XX quarter, quarter. the were plastic the with XXXX now loss quarter -- to last million down $XXX,XXX a line compares decrease in modality per from OVATION-X share. costs This with reported quarter year $X.X items million or results. $X.X in

from compared million $X.X quarter the clinical delivery manufacture for reflects the $X.X were the vaccine. General third million pilot nanoparticle IND-enabling from in-house Our a as professional prior of supplies our costs quarter to CMC to in million Other the year. $XX,XXX fees, $X.X expense, of of increase primarily the expenses development This studies capabilities the Phase systems the This compared and for investments. I'll of employee-related results due year. was were $X decrease and increased due ago. to comparable lower the trial $XXX,XXX prior year. was financial quarter in for expenses $XXX,XXX compensation nonoperating sorry, briefly for income the to plasma first short-term higher X costs year This for third insurance. of the I'm to well stock the noncash costs for this company's manufacturing as our on and first interest months administrative and and legal the COVID touch I/II period. just in million XXXX year DNA --

to X the For at-the-market expenses from this resulted of Bank the of period was used compared decrease Valley the expense the from to months same an company's our first the for first $XX.X which during for of $X.X million million million $X.X equity period. Cash XXXX, Cash sales the of facility of financing or $XX.X from loss The resulting in totaled for $X.X sale little million the with for a loan Silicon offset of months compares decrease of used million of onetime the over X $XX.X of early $X.X months stock reported XX, $XX was and million with X-month first loss convertible XXXX. months the of share. facility. by of of September $XX.X due 'XX million the Series preferred same of million, for $X.XX XX% same per X $XX.X of activities activities of net was a period This operating repayment under subsequent million that in period A $X.XX the by X million ended million XXXX, Operating redeemable XXXX. were year-ago a we've redemption a XXXX. in XXXX, primarily payment or interest $XX

$X.X have $X.X this of proceeds sale first of from earlier, And Jersey net sales in mentioned as received an of also NOLs anticipate we the year unused next. I additional We NOL that million and quarter we the of XXXX. million New

expenses Our pilot the earlier. I'll to fourth related balance PLACCINE development the back majority the the of in-house manufacturing development $X of are of of quarter. is the projected approximately for The call turn cash capabilities for to Corinne. mentioned modality, XXXX utilization million including our now

Corinne Goff

Thank immune of the on harnessing Imunon you, focused power the Jeff. tightly is system.

of people achieve with the to has available provide for our and is us more To we Scientific most committed cancer the Dr. Director and creating ensuring Professor immuno-oncology serves at Research Board our Center Disease Melanoma the of Sciences biology Director or Department while shareholders. Collaborations the Shukla, Our of to projects. and and Advisory goal end, leukemia strategy, Assistant Sachet Clinical Imunon Eclipse goal. to of that millions Anderson, potent with of immunity at our at where the help as additions are components the infectious durable the expand immunity Cancer Basic key Dana-Farber Dr. delighted Division in Ott, computational Institute; diseases, advisers that Patrick we Immunology value for significant Finance MD Clinical are to also for of he and of are or our Center talented cancer, Director evolution

third full combination subset them, with IMNN-XXX. milestones achievements with interim cancer, were exceptionally advance study data come. of quarter of and chemotherapy in PART recent IMNN-XXX more we OVATION-X in expected patients with busy reported particularly and the Among The inhibitors compelling and taking in a to weeks end of in

mid-XXXX. Our this top is milestone study from report to data in next line

human we control We with pathogens and build on also interest site only COVID-XX more Marburg demonstrating to concerns, in to which to We data will cost. And also the come With capabilities Alabama material, SARS-CoV-X of of of second virus technology virus. safety to modality entered of booster but advance others, to our be specifically of immunogenicity against development and in collaborations reliance by vaccines. is compelling we clinic data with reduce in the generated through quarter and to qualities a expected for across XXXX. monkeypox state-of-the-art risk unveiled in and next-generation into us in LASSA the And immunological intended clinical excellent pathogens on April seasonal vaccines. our manufacturing PLACCINE give Hanesville several and generated quality the response of our the IMNN-XXX, our of cancer not

week with the one-on-one the the your be questions, San Before we that Francisco, available with take in want mention concurrent will to Conference. community January annual JPMorgan Healthcare we meetings investment X I for of

contact please open like if questions. your firm, Investor our that, LHA, Operator? So a I schedule Relations the would you meeting. With to to call up

Operator

[Operator first comes from question H.C. Instructions] Bodnar Wainright. The Emily of

Emily Bodnar

I the recent want OVATION-X, had. to ask that data on you

about a you inhibitors had terms you've in mentioned previous that where in data had and a patients. patients. the of talked PARP benefit you had But obviously, So with readout you also benefit you assumingly BRCA-positive BRCA-negative in benefit

you think with you speak So to if discuss then there seeing the you specifically about next a you PARP to curious is IMNN-XXX synergy inhibitors? there thinking whether evaluate or think can steps, be you're PARP switch might you're just combination maybe with broadly and why And planning why how inhibitors?

Corinne Goff

So questions. I will let start your and maybe Khursheed answer also I'll

So you're absolutely correct.

you cut, which preliminary data we show last in BRCA-negative population. mature If we very data, and year, benefits did remember with

patients events. more have and we that Now more

are with the BRCA doesn't XX PARP with patients treated events ITT signature benefit answer. both give So arms a this population. molecular And inhibitors we showing because look specifically the the at full difficult with to said across in we

HRD-positive are demonstrated if BRCA-negative it PARP progression-free BRCA increase positive, inhibitors even -- patients. been receive it survival they patients has it As as is PARP can you inhibitors in that get know, patients

BRCA as bit HRD who in ovarian so patients designing very of description advanced is tumors which at. test you deficiency with be accurate cancer is look of wanted recombination for a And wanted in homologous to only know, common. half that HRD, of more our are group XX% we this And have women and to positive mutations.

we BRCA interesting And granularity. get data. So and very at as top the their treated PARPs the get regardless with status line then patients this look to we'll to it's data get to of

PARP the We are discussed here that PARP of administered is tumor IL-XX, for what what's after So advisers So with chemotherapy. kind is hypothesis PARP inhibitors that and terms our of we sensitizes our the this inhibitors. the happening inhibitors? call so the assumptions their in the IMNN-XXX with

potent are want? So -- into what a can sense, immuno turn which makes hepatitis you agent And cold thinking, modality IL-XX that's the because hot that a that's a as if they our being tumor. tumor very

path, than you'd progress, with what if sooner should like we'll and we as of in we to June. to I results them discuss want anticipation So to talk course, -- regulatory Maybe regulators, in add of the line to top Khursheed, the later said? we'll the have this

Khursheed Anwer

wanted mechanisms. I of kind Corinne, potential mean much to but I covered I you with Emily's that last just start part question, pretty just think if of you the address

I So positive you a know, treatment, was environment that CDX in report transitioned ratio increase tumor cells the in marker where from from Emily, as back that change the we suggests microenvironment in we study, the immunosuppressive did Phase to immunostimulatory. saw to immunosuppressive

before PARP So tumor as have environment against to now for Corinne be itself, potential the mechanism. sensitize PARP. tumor you environment you X That the changed more has other tumor. fighting that words, could In for in, this come be said,

antigen. potentially that's theoretically, good We're new that and it, PARP if potentially repair that will a happen think makes potential it As that's sense. but environment you saying And death, the cell you be have diet stimulatory I know, not response? that Is causes doesn't releases mechanism. in

IT there out But some BRCA-positive, patients, as are more There's it to it's That's there's other some have systematic. well BRCA-negative. that deficient lot And the deficiency. we define signature tumor was recombinant about in of artificial are Now in in a And first sell ovarian also, there. but in enzyme this as wise, Initially, data. a you variability current-core homologous patients. more part BRCA-negative. your learn that point early of cancer. also was question molecular lot

see the BRCA-positive, the if make into correlate. some So we're really look sub-ties and to not what's trying to just deficiency also micro you BRCA-negative. better But of to database signature, extent understand can the further

and lower what these the your that, prices then the think because trying about we're but you the some prior next now understand also further I understand break further sample down. really XX you have that's into to look If results, mechanism, already through But going maybe what's type specific application. us more more to limited ask of that But of about a to this you PARP you signature application shape type broad ongoing as learn to direct come up I will maybe future perhaps strategy. data direction our or certainly think studies, like you do your from to study, combination in, more

Operator

question Alliance comes Molloy from next Our James of Global Partners.

James Molloy

just looks? get through the much second OVATION-X on thoughts walk data on I next mid potential year. the next trial Phase And III trial, we in are the come the you quarter I the trial, Phase here interim here of what the out might the how Avastin be Phase the design interim then from on I/II IIb design or in to look? your want for should Phase data Can potential of anticipating that that? depend What trial III, what know the coming steps Avastin be up or on data here,

Corinne Goff

designation the in that in what on. considerably imagine development can current lines, the something program, as And the we could are interested enrolling discussing we'll mentioned We for on a be pathway. the very that in with So notably regulatory I be with shorten would have could OVATION-X we potential FDA breakthrough time continue we Phase that's is II. the that so you mind working

program XXX the with we -- II As patients. right, so is exploratory, Phase only mentioned,

would of to with patients included of in number the So increase subpopulation certainly, treated need at the the PARP inhibitors. trial. look would we we And

not in plan at speak we development the we regulators, don't mind we you stage. do until this address But before that's we to mrd right this now. study? we point So want have speak -- the what on the with have regulators, any I have have Khursheed, we unless comment confirmed And with

Khursheed Anwer

No, cured think you've I it.

exactly help that's formulating be from think in or still and our agency we're I important. perhaps just feedback will strategy

Corinne Goff

data. the have enrollment MRD interesting study, we would is on like some from a expect we so year already And what

protocol So for that, do would accounted from what data of do us. want maybe, I number And think, on comment this, we in Khursheed? comment translational has you Khursheed, design, informational on which the to you Do super for of this this? also the investment study, a be want to expect

Khursheed Anwer

Yes.

of maybe course information . said, second of next will MRD you Of quarter anticipated is as kind course, James, from study. year

IMNN-XXX study, we MRD first Avastin the in the be this with So is human. testing time will

We have before. done that never

is now in adjuvant setting has a approved. So new Avastin been

the Phase I part really the study with Avastin. lead first think of So I look the is safety to at

So want out don't think we any that that's I way. anticipate We to issue. get

something, to safe that's and population. then I guess, it's the study up combination move So on from be will that open into

patients lower Now X survival. we'll data what that of as And to we when would peritoneum chemo. you therapy, looking cytoreductive nothing removed by the be Avastin, second residual be happens anticipated important will the more then and surgery then anticipate disease cycles and is is certainly get the study X get another the after. burden, preclinical month surgically road, the surgery of quarter. down time, to really But burden because this is benefit enrollment have after by said, but and Corinne cycles chemo, longer with again And reduce maintenance the IMNN-XXX to residual we anticipate after disease X that at and now in tumor

disease what's XX%. known, is XX% disease those how to have seen So patients. safety have residual that said, promise be we're look of I second about patients have which versus see complete. have minimal to to residual like we patients second the anticipate laparoscopy, will you get in we'll I what expect that, many about to the road trying finance can't maybe quarter, the we some versus it down But

that probably all of do of research, all are collected. we sort done translational lot data So samples of patients collecting is have been might have also understand be will some biology that the a tumor in we coming but the the when

I safety and update data some So the X obviously, think on animal endpoints. or secondary maybe data plus redial disease, PFS

have different or years with periods. OVATION-X, over time the been updating the As a community we

a lot have that. it of to priority the we'll clearly, understand combination. But will some translational study So component to of this

James Molloy

Great. And review R&D virus. about that cooperative talking the potential down I a of signed third butter the you're LASSA or virus, also here Does proprietary NIAID it agreement you the LASSA in guys see road? quarter

Corinne Goff

Yes. That's a good question.

I this develop want partnerships as Khursheed, any, interested, why with we would modality, NIH? at that is of we And candidates? with place But you have not? if to the on elaborate maybe, So vaccine mentioned look to development agreement the

Khursheed Anwer

course. of Yes,

couple have So that. years, we have course, platform, history PLACCINE we the kind on as initially, -- of James, mean, know, embarked you of a that new suggests of the we survive past I as could

So proof-of-concept many has application our as goal indication opportunities to can. demonstrate we been and in or

like facility at looked need LASSA have IND approaches LASSA. in you Africa, collaborations. in at biosafety force clinical past. there, And trials. some for where would at have done some have we the have virus They They some looking with level different ground is including Some on they West is Mali,

So commercial out not there's for incidents look as come as a potential be heading America may as doesn't huge, on perhaps where in it's Corinne west. South today, said, also as coming company, more increasing the report but it and very LASSA

different of that interested results in So animal would to then who knows, but of is technology approach are be in West sort pursuing concept the certainly NIAID for LASSA virus. in NIAID, another our Africa. see if And positive the studies, kind

to defer not NIAID company our if So but collaboration, I of that role through lead not as big proof to that's some do concept. at be a commercial aspect, thirdly, But sort such, want taking point. further, of company-wise, mean, why And I that.

now, our Karen on may on that. comment SARS-CoV-X. I focus But think right

James Molloy

last of I Okay. question quarters. Jeff, kind Great. just Last Jeff, OpEx has trending the could. for if few down been

going good should You we OpEx bumping Is perhaps this cash. through guys up job, Or going we level 'XX? forward? start anticipate seeing doing the are shepherding a

Jeffrey W. Church

anticipate the enrolled. breakthrough We quarter program is funded we'll study. will million of OVATION-X But follow-up the doing our range, and being cash the driver fully to sort that. largely in Yes. $X cancer We're manage mentioned, that foundation. we the And Phase the a utilization is on the Avastin I/II just low as with by a the big be that then

of $X.XX to going quarterly to to $X a million utilization we're So manage million. cash

Operator

Dolliver Kemp from Brookline comes from The Markets. Capital next question

Brian Kemp Dolliver

couple Avastin. about in have I IMNN-XXX combination questions with So a of trial the

you expect activate to First, Dana-Farber when MSK? and do

Corinne Goff

soon. very yes, Kemp,

want answer? that announced not board Khursheed, a give my on -- least to but you color at we're will MSK be have be it We bit explaining yet, do more pretty. there to will

Khursheed Anwer

right. their a with we is site did a respond them Corinne call of visit weeks Exactly, did to standards. ago. couple Yes. initiation caution We IRB

think I be soon So they could activated. very

I participate part The Dana-Farber But trial. II the Phase other had Phase they of is for the part. from one very Hopkins beginning would the from Johns

should we So with said, on committees, approvals as should A from be of just direction. be been -- all made them. have board. has the good contract, coming announcement making hiccups setting be It's their that the unexpected, work lot should no completed headwinds paper up they different Corinne MSK in we basically the

soon. very coming is MSK up likely So

Brian Kemp Dolliver

cost? availability this have great. believe, but That's then to the carboplatin And I able terms also that How supply. been of, that's is trial and using short is comparator both you been a, arm, in in in manage

Khursheed Anwer

this -- centers with issue. a that's XXXX names. mean, I issue a are We haven't into remember, did was I studies good the that you Yes. run big that no, are we if mean, But our doing we Doxil, back big in really question.

So in say, to attention and center not the And MD Anderson back chemotherapy has is in having you're cancer terms deficiency. brought right, any this investigators carboplatin of paclitaxel.

the [ drug, platinum-based to cisplatin deficiency a of any having sites is these haven't yet, ] course, drive Cost heard big from really centers issues. care normally So But is another, center used. certainly a given patients. is we of

that forecasting cisplatin you with heard there But drug. I is may platinum problem always center haven't but available cancer about to anticipate. as another not I'm side anything these So plan any

concern something, have really say out an be because lot was would or named. that don't we haven't told docs sellers. as centers, XX sites small could -- and there had I you so a far to and point with about been probably a did sites be want these that about there so. of perhaps So issue we Maybe being X

we really, by haven't that, issue into told sites the yet. look I been down the mean, -- I know road don't certainly. I So

Corinne Goff

by Foundation? Break are Yes. Through And [indiscernible] of the cost paid Cancer

Brian Kemp Dolliver

Right.

questions, apologize. X I So

clear those is the But The of I and because be you completion think -- first going timing you'll wasn't to data it just I of availability enrollment provide for some this up trial, of how want understood one sure up the line I anticipated line and require breaking the first together. set repeat to interim to information. was

Corinne Goff

right. All

start, I'll will continue. I So and Khursheed let

the which will come if Khursheed, the enrollment. that phase part So us. trial, first an what least anticipate of question? acceleration enrollment answer on of we combination the of you for of you the the be at investigators Avastin, could pinning cautiously see safety the analysis more second the board, is the are And XXX But of please, and in centers that's will as course,

Khursheed Anwer

Right.

if issue. a I So signal there apologize was

of because not So what with has I data be the sort course, in response combined question, James' GEN-X. we would safety, had action believe, been that to, initial said of

So to the we finish study all I the depends Phase mean part hope of enrollment. I out. on that

clearance even from sites on of that least years initially, that. over been would quarterly And results a X probably sites is would sites sites. laparoscopy and in more in update Corinne look completing time of more board, say, trying would enrollment second and at more X then to get can about I have new with And we combination put get But expand enrollment but I quarter patients. a at safe quarter here. second couple that in say For on are maybe we complete can or would terms second so. study, and begin into to update think be I Jeff chime perhaps plus the the safety least place and to we in on, more if Indeed, this

data immediate open-label data, trickle I update down, efficacy and this can is maybe safety the So some study. we think

maybe X a anticipating X we some mature. endpoint. hopefully. overall I to probably sites. meaningful long So say, some a will data, significant and could survival time years, also within years, we with this data. get Again, second That But frustrated take is more are laparoscopy, what is within longer would But look certainly,

Corinne Goff

we give centers to very at cannot Right. lines more enroll. time precise stage, this And Kemp, where we're waiting for

it's assessment preliminary really. So a

Brian Kemp Dolliver

against the No, as will those Or question Jeff, the that's revenue? Will your up reimbursement. last R&D trial cancer and the breakthrough net expense? relates grant for super. show just those just and it the reimbursements essentially And to

Jeffrey W. Church

the to expense. going what be how anticipate. we we're will R&D We'll former, treat as It be just paying

Operator

question next Small-Cap comes Zacks Bautz Research. from The from David

David Bautz

on the I/II this update have for seasonal question morning. just COVID the Thanks trial. for the I a booster Phase vaccine plan

be to Phase the that an trial efficacy II? assuming look is study to healthy you I'm volunteers, in Phase So will safety in going do but then study I

Corinne Goff

question. you David, your thank for Yes.

in will already, right? nutrizing injection you after that So data, immune rapidly development the we have Phase So in vaccine. quite vaccine the I response antibody data have you the get of

I/II. give that's us I And already the program, Phase why data. So are design will we looking of our that the in Phase for

Phase So in we'll the enrolling dose. a simply with chosen continue program II

David Bautz

then I an And Phase the will haven't outcome... Okay. efficacy

Corinne Goff

and [indiscernible] efficacy -- yes, reactogenicity immunogenicity, well. efficacy as outcome

Khursheed Anwer

Yes.

know, you challenging being vaccine efficacy as is So not human trials, right. really

So the antibodies -- baseline. neutralizing what above at, antibody you it's titers really, look really that's of the

what So I think probably that's to essentially efficacy you're maybe referring part.

variant baseline the at against particular in that II, the so be time. from targeting concern at much we titles this looking gone variant will that up we and the have of are that Phase So of

of the neutralizing basically, opposed in titers antibody to baseline. studies in as cancer. market, measure above vaccine So ride therapeutic a That's typically efficacy the

that Phase So yes, II. in at looking we will be

Operator

our would over to for conference the remarks. This turn any concludes question-and-answer back management closing session. like to I

Corinne Goff

you. Thank

ovarian of work to And we the So next also here about the what looks we offer women protection, and at future superior virus. no rapidly immuno-oncology to data much is. to and breadth Have manufactured describe excited very using vaccine our reporting pathogen of device be or can durability cancer are We've be progress. respond Phase evolving the technology that to our in need stable on in work, providing believe options and very to our to as holds nice informed compliance look summer. vision a vaccines current phrase that safe our are very temperatures, are keeping of with interesting. excellent maximization To forward spring, We of and that's with you been next II workable afternoon. exactly for promise better effective provider our terms vaccines for of in

Operator

presentation, you you concluded. disconnect. attending today's The Thank for may now now conference has

Imunon (IMNN) 14 Nov 232023 Q3 Earnings call transcript